文献速递心律失常瓣膜病与结构性心脏病

二尖瓣手术联合房颤消融后的起搏器植入

Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

本研究基于随机对照试验,纳入243例房颤且无既往起搏器植入的二尖瓣手术患者,随机分为单纯手术组和手术联合消融组(进一步分为肺静脉隔离或双心房迷宫术)。结果显示,消融、多瓣膜手术和NYHA III/IV级是起搏器植入的独立危险因素,起搏器植入与1年死亡率升高相关。

要点

  • 房颤消融、多瓣膜手术和NYHA III/IV级增加起搏器植入风险。
  • 二尖瓣手术后起搏器植入与1年死亡率升高相关。
  • 起搏器植入未显著增加30天再入院率。

核心结论

  • 房颤消融、多瓣膜手术和NYHA功能III/IV级与永久起搏风险增加相关。
  • 二尖瓣手术后起搏器植入与1年死亡率显著增加相关。

研究设计与样本

  • 随机对照试验,纳入243例房颤且无既往起搏器植入的二尖瓣手术患者。
  • 患者随机分为单纯二尖瓣手术组(n=117)或手术联合消融组(n=126)。
  • 消融组进一步随机分为肺静脉隔离(n=62)或双心房迷宫术(n=64)。

主要发现

  • 起搏器植入频率:单纯手术组7.7%,手术+肺静脉隔离组16.1%,手术+双心房迷宫术组25%。
  • 消融、多瓣膜手术和NYHA III/IV级是起搏器植入的独立危险因素。
  • 起搏器植入与1年死亡率升高相关(HR: 3.21; 95%CI: 1.01-10.17; p=0.05),校正随机分组、年龄和NYHA分级后。
  • 起搏器植入未增加30天再入院率(HR: 1.43; 95%CI: 0.50-4.05; p=0.50)。

临床怎么用

  • 对于接受二尖瓣手术联合房颤消融的患者,应评估起搏器植入风险,尤其是多瓣膜手术和NYHA III/IV级患者。
  • 术后起搏器植入可能提示预后不良,需加强随访。

局限性

  • 研究为随机试验的事后分析,样本量有限。
  • 起搏器植入与死亡率的关联为观察性,不能确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of permanent pacemaker (PPM) implantation is higher following mitral valve surgery (MVS) with ablation for atrial fibrillation (AF) compared with MVS alone. OBJECTIVES: This study identified risk factors and outcomes associated with PPM implantation in a randomized trial that evaluated ablation for AF in patients who underwent MVS. METHODS: A total of 243 patients with AF and without previous PPM placement were randomly assigned to MVS alone (n = 117) or MVS + ablation (n = 126). Patients in the ablation group were further randomized to pulmonary vein isolation (PVI) (n = 62) or the biatrial maze procedure (n = 64). Using competing risk models, this study examined the association among PPM and baseline and operative risk factors, and the effect of PPM on time to discharge, readmissions, and 1-year mortality. RESULTS: Thirty-five patients received a PPM within the first year (14.4%), 29 (83%) underwent implantation during the index hospitalization. The frequency of PPM implantation was 7.7% in patients randomized to MVS alone, 16.1% in MVS + PVI, and 25% in MVS + biatrial maze. The indications for PPM were similar among patients who underwent MVS with and without ablation. Ablation, multivalve surgery, and New York Heart Association functional (NYHA) functional class III/IV were independent risk factors for PPM implantation. Length of stay post-surgery was longer in patients who received PPMs, but it was not significant when adjusted for randomization assignment (MVS vs. ablation) and age (hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.61 to 1.08; p = 0.14). PPM implantation did not increase 30-day readmission rate (HR: 1.43; 95% CI: 0.50 to 4.05; p = 0.50). The need for PPM was associated with a higher risk of 1-year mortality (HR: 3.21; 95% CI: 1.01 to 10.17; p = 0.05) after adjustment for randomization assignment, age, and NYHA functional class. CONCLUSIONS: AF ablation, multivalve surgery, and NYHA functional class III/IV were associated with an increased risk for permanent pacing. PPM implantation following MVS was associated with a significant increase in 1-year mortality. (Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery; NCT00903370).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. DeRose JJ, Mancini DM, Chang HL, et al. Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation. J Am Coll Cardiol. 2019. PMID: 31097163. doi:10.1016/j.jacc.2019.02.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。